JANX vs NDAQ · rev $10.3M vs P/E 41, rev $2.53B
Janux Therapeutics Inc (JANX) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Janux Therapeutics Inc (JANX) is a biotechnology company listed on US.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
Latest reported JANX revenue for 2026-06-30 was $10.3M. Net income was -$22.0M. JANX currently screens at market cap $1.49B.
Latest reported NDAQ revenue for 2026-06-30 was $2.53B. Net income was $507.0M. Revenue was up 18.5% from 2026-03-31 to 2026-06-30. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
JANX currently screens at market cap $1.49B. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the JANX and NDAQ stock pages for the full models.
Not investment advice.